AC Immune SA
ACIU
$1.77
-$0.11-5.85%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -95.61% | 3,778.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -95.61% | 3,778.43% | |||
| Cost of Revenue | 7.35% | -11.65% | |||
| Gross Profit | -231.12% | 169.93% | |||
| SG&A Expenses | 4.56% | -13.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 27.73% | 51.43% | |||
| Total Operating Expenses | 6.81% | -12.03% | |||
| Operating Income | -352.27% | 136.26% | |||
| Income Before Tax | -382.68% | 125.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -382.73% | 125.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -382.73% | 125.28% | |||
| EBIT | -352.27% | 136.26% | |||
| EBITDA | -335.76% | 138.75% | |||
| EPS Basic | -382.42% | 125.20% | |||
| Normalized Basic EPS | -382.41% | 125.19% | |||
| EPS Diluted | -416.44% | 122.86% | |||
| Normalized Diluted EPS | -385.28% | 124.94% | |||
| Average Basic Shares Outstanding | 0.15% | 0.29% | |||
| Average Diluted Shares Outstanding | -0.86% | 1.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
